ABSTRACT
Background: Reliving distressing memories is a core component of treatments for post-traumatic stress disorder (PTSD) and prolonged grief disorder (PGD). There is little understanding of how reliving these memories functions in the treatment of these disorders.Objective: This study investigated whether reliving functions comparably in the treatment of PTSD and PGD, and whether it is comparably related to treatment outcome.Method: This study conducted a reanalysis of patients with either PTSD (n = 55) or PGD (n = 45) who underwent treatments that comprised at least four sessions of reliving memories of either their traumatic experience or the loss of the deceased person.Results: PTSD participants displayed greater habituation of distress across sessions during reliving than PGD participants. Between-session reduction in distress during reliving was associated with symptom remission in PTSD, but this pattern was not observed in PGD.Conclusion: This pattern of findings indicates that although reliving appears to be a useful strategy for treating both PTSD and PGD, this strategy does not function comparably in the two conditions and may involve distinct mechanisms.
Reliving distressing memories is key to treatment of PTSD and prolonged grief disorder.Distress during memory reliving habituated in PTSD treatment more than in treatment of grief.Habituation of distress during treatment predicted remission of symptoms in PTSD but not grief.
Subject(s)
Grief , Stress Disorders, Post-Traumatic , Humans , Stress Disorders, Post-Traumatic/therapy , Prolonged Grief Disorder , Habituation, Psychophysiologic , Treatment OutcomeABSTRACT
INTRODUCTION: The administration of multiple esketamine doses has shown efficacy for unipolar and bipolar treatment-resistant depression (TRD). Nevertheless, the probability of responding or not after each dose in the real-world remains unknown. This study aimed to estimate it throughout four doses of esketamine, administrated via subcutaneous (SC). MATERIAL AND METHODS: We conducted a retrospective analysis of a case series of 70 patients with TRD who received treatment from the esketamine assistance program at Federal University of Sao Paulo, between April 2017 and December 2018. The SC injections were administrated weekly at a dose of 0.5-1.0mg/kg, in conjunction with patients' psychotropic drugs. Response was defined as a decrease of at least 50% in the Montgomery-Åsberg Depression Rating Scale between baseline and 24h after dose. We used hidden Markov modeling in order to estimate de probability of response after each esketamine injection. RESULTS: The probability of a patient that was a "non-responder" to become a "responder" following a SC injection of esketamine was 17.30% and the probability that this patient remains a "non-responder" was 82.70%. The probability of a patient that was a "responder" to remain as a "responder" was 95%. CONCLUSIONS: Patients with TRD who had not responded after the first dose of esketamine, still had a chance of responding after the subsequent dose administrated via SC.
Subject(s)
Antidepressive Agents , Depression , Antidepressive Agents/therapeutic use , Depression/drug therapy , Humans , Injections, Subcutaneous , Ketamine , Probability , Retrospective StudiesABSTRACT
Introduction The administration of multiple esketamine doses has shown efficacy for unipolar and bipolar treatment-resistant depression (TRD). Nevertheless, the probability of responding or not after each dose in the real-world remains unknown. This study aimed to estimate it throughout four doses of esketamine, administrated via subcutaneous (SC). Material and methods We conducted a retrospective analysis of a case series of 70 patients with TRD who received treatment from the esketamine assistance program at Federal University of Sao Paulo, between April 2017 and December 2018. The SC injections were administrated weekly at a dose of 0.51.0mg/kg, in conjunction with patients psychotropic drugs. Response was defined as a decrease of at least 50% in the Montgomery-Åsberg Depression Rating Scale between baseline and 24h after dose. We used hidden Markov modeling in order to estimate de probability of response after each esketamine injection. Results The probability of a patient that was a non-responder to become a responder following a SC injection of esketamine was 17.30% and the probability that this patient remains a non-responder was 82.70%. The probability of a patient that was a responder to remain as a responder was 95%. Conclusions Patients with TRD who had not responded after the first dose of esketamine, still had a chance of responding after the subsequent dose administrated via SC. (AU)
Introducción La administración de dosis múltiples de esketamina ha demostrado su eficacia para el tratamiento de la depresión unipolar y bipolar resistente al tratamiento (TRD). Sin embargo, sigue siendo una incógnita la probabilidad de responder o no tras cada dosis en el mundo real. El objetivo de este estudio fue calcular dicha probabilidad durante la administración vía subcutánea (SC) de cuatro dosis de esketamina. Material y métodos Realizamos un análisis retrospectivo de una serie de casos de 70 pacientes con TRD, que recibieron tratamiento a través del programa de asistencia con esketamina en la Universidad Federal University de Sao Paulo, entre abril de 2017 y diciembre de 2018. Las inyecciones SC se administraron semanalmente, a dosis de 0,5-1mg/kg, junto con los medicamentos psicotrópicos de los pacientes. Se definió la respuesta como una reducción de al menos el 50% en la Escala de Calificación de la Depresión de Montgomery-Åsberg entre el valor basal y las 24 horas posteriores a la administración de la dosis. Utilizamos el modelo oculto de Markov para calcular la probabilidad de respuesta tras cada inyección de esketamina. Resultados La probabilidad de que un paciente que fuera «no respondedor» se convirtiera en «respondedor», tras una inyección SC de esketamina fue del 17,3%, y la probabilidad de que este paciente siguiera siendo «no respondedor» fue del 82,7%. La probabilidad de que un paciente que fuera «respondedor» lo siguiera siendo fue del 95%. Conclusiones Los pacientes con TRD que no han respondido a la primera dosis de esketamina, tienen probabilidad de respuesta tras la administración de las siguientes dosis por vía SC. (AU)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Ketamine/analogs & derivatives , Ketamine/administration & dosage , Ketamine/therapeutic use , Injections, Subcutaneous , Depressive Disorder, Treatment-Resistant/drug therapy , Depressive Disorder, Treatment-Resistant/therapy , Bipolar Disorder/drug therapy , Bipolar Disorder/therapy , Depressive Disorder/drug therapy , Depressive Disorder/therapy , BrazilABSTRACT
INTRODUCTION: The administration of multiple esketamine doses has shown efficacy for unipolar and bipolar treatment-resistant depression (TRD). Nevertheless, the probability of responding or not after each dose in the real-world remains unknown. This study aimed to estimate it throughout four doses of esketamine, administrated via subcutaneous (SC). MATERIAL AND METHODS: We conducted a retrospective analysis of a case series of 70 patients with TRD who received treatment from the esketamine assistance program at Federal University of Sao Paulo, between April 2017 and December 2018. The SC injections were administrated weekly at a dose of 0.5-1.0mg/kg, in conjunction with patients' psychotropic drugs. Response was defined as a decrease of at least 50% in the Montgomery-Åsberg Depression Rating Scale between baseline and 24h after dose. We used hidden Markov modeling in order to estimate de probability of response after each esketamine injection. RESULTS: The probability of a patient that was a "non-responder" to become a "responder" following a SC injection of esketamine was 17.30% and the probability that this patient remains a "non-responder" was 82.70%. The probability of a patient that was a "responder" to remain as a "responder" was 95%. CONCLUSIONS: Patients with TRD who had not responded after the first dose of esketamine, still had a chance of responding after the subsequent dose administrated via SC.
ABSTRACT
Lung cancer is a fairly common malignancy. An early diagnosis and a reliable staging and re-staging with the aim to detect both local and distant relapse are of utmost importance in planning the therapeutic management. The imaging diagnostic work-up of patients with lung cancer usually includes conventional imaging (chest X-ray, contrast-enhanced CT, bone scan) and more recently 18F-FDG PET/CT. Great advances in the management of lung cancer are based on the information provided by 18F-FDG PET/CT, as it supplies both metabolic and anatomic information (better localisation). There is vast evidence in the literature demonstrating its utility in (a) characterising benign versus malignant solitary nodules, (b) staging and re-staging lung cancer, (c) guiding the type of therapy, (d) monitoring treatment response and (e) predicting outcome. In particular, given its specificity in differentiating 18F-FDG-avid relapse from post-surgical changes or post-radiation fibrosis (which do not take up 18F-FDG), PET/CT can detect recurrent disease after initial treatment and (being a whole-body technique) has demonstrated high accuracy in the detection of distant metastases or secondary tumours. In conclusion, 18F-FDG PET/CT can be considered a highly accurate and reliable method for staging and re-staging lung cancer, and is highly effective in guiding personalised therapies.
Subject(s)
Lung Neoplasms/diagnostic imaging , Positron Emission Tomography Computed Tomography/methods , Chemoradiotherapy , Clinical Decision-Making , Combined Modality Therapy , Cost-Benefit Analysis , Diagnosis, Differential , Early Diagnosis , Fibrosis , Fluorine Radioisotopes , Fluorodeoxyglucose F18 , Humans , Lung Diseases/diagnosis , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Lung Neoplasms/therapy , Meta-Analysis as Topic , Neoplasm Metastasis , Neoplasm Recurrence, Local/diagnostic imaging , Neoplasm Staging/methods , Pneumonectomy , Positron Emission Tomography Computed Tomography/economics , Radiofrequency Ablation , Radiopharmaceuticals , Radiosurgery , Sensitivity and Specificity , Treatment OutcomeABSTRACT
OBJECTIVE: To evaluate the association between weight loss and changes in disease activity in patients with psoriatic arthritis (PsA). METHODS: We performed a systematic review of the literature, with searches in Medline, Embase and Cochrane Central Library from inception until April 2015. INCLUSION CRITERIA: 1) randomized controlled trials (RCT); 2) PsA patients; 3) interventions were any intervention aimed at weight control; and 4) a PsA activity-related outcome measure was evaluated. Risks of bias were assessed by the Cochrane Collaboration scale. RESULTS: Of the 215 articles identified, only 2 RCT met the inclusion criteria, 1 in abstract format. Both showed moderate risk of bias. Patients who managed to lose weight-by any method-had better results in terms of activity and inflammation. The percentage of weight loss correlated moderately with changes in inflammatory outcomes. CONCLUSION: Weight loss in PsA could be associated with less inflammation; however, the evidence to support this is limited.
Subject(s)
Arthritis, Psoriatic/physiopathology , Obesity/therapy , Weight Loss/physiology , Arthritis, Psoriatic/complications , Arthritis, Psoriatic/diagnosis , Arthritis, Psoriatic/therapy , Humans , Obesity/complications , Severity of Illness Index , Treatment OutcomeABSTRACT
OBJECTIVE: To investigate the relationship between maximum standardised uptake value (SUVmax) of ovarian lesions and histopathology subtypes, and their involvement in the response and prognosis of patients with epithelial ovarian carcinoma (EOC). MATERIAL AND METHODS: A retrospective analysis of 31 patients with EOC and 18F-FDG-PET/CT before treatment, including an assessment of the SUVmax of ovarian lesion. Histopathological diagnosis and follow-up was performed. A study was made on the relationship between the SUVmax and histological type (type I and II) and tumour stage, as well as the role of various parameters (SUVmax, histology, stage) on the patient outcomes (complete response [CR], overall survival [OS], disease-free survival [DFS], and disease-free [DF] status, at 12 and 24 months). RESULTS: The medium SUVmax in type I lesions was lower than in type II (6.3 and 9.3, respectively; P=.03). A 7.1 cut-off was set for SUVmax in order to identify type II EOC (sensitivity: 77.8%, specificity: 69.2%; AUC=0.748; P=.02). No significant relationship was found between tumour stage and SUVmax. CR was more common in early stages; relative risk (RR) of 1.64; P=.003, as well as in type I tumours and a lower SUVmax. Tumour stage was decisive in DFS (P=.04), LE24m (0.07) and OS (P=.08). Longer DFS and a higher percentage of DF 24m were observed in type I tumours (RR: 1.32; P=.26). CONCLUSIONS: SUVmax was related to EOC histology, so could predict the response and prognosis of these patients. No association was found between glycolytic activity of the primary tumor with the response and prognosis.
Subject(s)
Neoplasms, Glandular and Epithelial/diagnostic imaging , Ovarian Neoplasms/diagnostic imaging , Positron Emission Tomography Computed Tomography , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Ovarian Epithelial , Combined Modality Therapy , Disease-Free Survival , Female , Fluorine Radioisotopes , Fluorodeoxyglucose F18 , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Middle Aged , Models, Biological , Neoadjuvant Therapy , Neoplasms, Glandular and Epithelial/etiology , Neoplasms, Glandular and Epithelial/pathology , Neoplasms, Glandular and Epithelial/therapy , Ovarian Neoplasms/etiology , Ovarian Neoplasms/pathology , Ovarian Neoplasms/therapy , Ovariectomy , Prognosis , Radiopharmaceuticals , Retrospective StudiesABSTRACT
Se realizó un estudio observacional descriptivo, longitudinal y retrospectivo de 46 pacientes con cáncer pulmonar de células pequeñas, diagnosticados histopatológicamente y tratados por el Grupo de Atención a Pacientes con Tumores de Pulmón del Hospital Provincial Clínicoquirúrgico Docente Saturnino Lora Torres de Santiago de Cuba, desde enero del 2002 hasta diciembre del 2014, con vistas a identificar las características clínicas y evolutivas en ellos, además de evaluar su supervivencia global. La enfermedad predominó en el sexo masculino, sobre todo en las edades de 55 a 74 años, y sus formas de presentación más frecuentes fueron la bronconeumónica y la hiliar infiltrativa pulmonar, detectadas de manera clínica y radiológica, respectivamente. Por otra parte, el diagnóstico histológico se obtuvo principalmente a través de la broncoscopia con biopsia y el esputo citológico, en una etapa limitada, y aunque en la mayoría de los pacientes se pudo aplicar como tratamiento de primera línea la combinación de carboplatino y etopósido, la supervivencia al año fue menor que una tercera parte del total de la serie(AU)
A descriptive, longitudinal and retrospective observational study of 46 patients with small-cell lung cancer, diagnosed histopathologically and treated by the Care Group to patients with lung tumors in Saturnino Lora Torres Teaching Clinical Surgical Provincial Hospital in Santiago de Cuba, was carried out from January, 2002 to December, 2014, aimed at identifying their clinical features and evaluating their global survival. The disease prevailed in the male sex, mainly in the 55 to 74 age group, and its most frequent presentation were the bronchopneumonic and lung infiltrative hilar types, detected in a clinical and radiological way, respectively. On the other hand, the histological diagnostic was obtained mainly through the bronchoscopy with biopsy and the cytological sputum, in a limited stage, and although in most of the patients the carboplatin and etoposide combination could be apply as first line treatment, the survival at a year was less than a third part of the whole series(AU)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Lung Neoplasms/drug therapy , Lung Neoplasms/therapy , Survivorship , Small Cell Lung Carcinoma/drug therapy , Epidemiology, Descriptive , Retrospective Studies , Longitudinal Studies , Observational Studies as TopicABSTRACT
Se realizó un estudio observacional descriptivo, longitudinal y retrospectivo de 46 pacientes con cáncer pulmonar de células pequeñas, diagnosticados histopatológicamente y tratados por el Grupo de Atención a Pacientes con Tumores de Pulmón del Hospital Provincial Clínicoquirúrgico Docente "Saturnino Lora Torres" de Santiago de Cuba, desde enero del 2002 hasta diciembre del 2014, con vistas a identificar las características clínicas y evolutivas en ellos, además de evaluar su supervivencia global. La enfermedad predominó en el sexo masculino, sobre todo en las edades de 55 a 74 años, y sus formas de presentación más frecuentes fueron la bronconeumónica y la hiliar infiltrativa pulmonar, detectadas de manera clínica y radiológica, respectivamente. Por otra parte, el diagnóstico histológico se obtuvo principalmente a través de la broncoscopia con biopsia y el esputo citológico, en una etapa limitada, y aunque en la mayoría de los pacientes se pudo aplicar como tratamiento de primera línea la combinación de carboplatino y etopósido, la supervivencia al año fue menor que una tercera parte del total de la serie.
A descriptive, longitudinal and retrospective observational study of 46 patients with small-cell lung cancer, diagnosed histopathologically and treated by the Care Group to patients with lung tumors in "Saturnino Lora Torres" Teaching Clinical Surgical Provincial Hospital in Santiago de Cuba, was carried out from January, 2002 to December, 2014, aimed at identifying their clinical features and evaluating their global survival. The disease prevailed in the male sex, mainly in the 55 to 74 age group, and its most frequent presentation were the bronchopneumonic and lung infiltrative hilar types, detected in a clinical and radiological way, respectively. On the other hand, the histological diagnostic was obtained mainly through the bronchoscopy with biopsy and the cytological sputum, in a limited stage, and although in most of the patients the carboplatin and etoposide combination could be apply as first line treatment, the survival at a year was less than a third part of the whole series.
Subject(s)
Lung Neoplasms/diagnosis , Lung Neoplasms/therapy , Drug Therapy , SurvivorshipABSTRACT
PURPOSE: To explore the relation between tumor kinetic assessed by (18)F-FDG PET and final neoadjuvant chemotherapy (NC) response within a molecular phenotype perspective. MATERIAL AND METHODS: Prospective study included 144 women with breast cancer. All patients underwent a dual-time point (18)F-FDG PET/CT previous to NC. The retention index (RI), between SUV-1 and SUV-2 was calculated. Molecular subtypes were re-grouped in low, intermediate and high-risk biological phenotypes. After NC, all residual primary tumor specimens were histopathologically classified in tumor regression grades (TRG) and response groups. The relation between SUV-1, SUV-2 and RI with the TRG and response groups was evaluated in all molecular subtypes and in accordance with the risk categories. RESULTS: Responder's lesions showed significant greater SUVmax compared to non-responders. The RI value did not show any significant relation with response. Attending to molecular phenotypes, statistical differences were observed with greater SUV for responders having high-risk molecular subtypes. CONCLUSION: Glycolytic tumor characteristics showed a significant correlation with NC response and dependence of risk phenotype.
Subject(s)
Breast Neoplasms/diagnostic imaging , Breast Neoplasms/drug therapy , Neoadjuvant Therapy , Positron Emission Tomography Computed Tomography , Biomarkers , Breast Neoplasms/genetics , Female , Humans , Phenotype , Prospective StudiesABSTRACT
BACKGROUND: Imaging may be useful for monitoring response to therapy. Within the OMERACT proposal for the core set domains for outcome measures in chronic gout, serum urate levels, recurrence of gouty flares, tophus regression, and joint damage imaging have been included, among other proposed issues. OBJECTIVES: To perform a systematic literature review of the usefulness of magnetic resonance imaging (MRI) and ultrasound (US) on assessment of treatment response in patients with gout. METHODS: MEDLINE, EMBASE, Cochrane Library (up to February 2012), and abstracts presented at the 2010 and 2011 meetings of the American College of Rheumatology and European League Against Rheumatism, were searched for treatment studies of any duration and therapeutic options, examining the ability of MRI/US to assess treatment response in gouty patients. Meta-analyses, systematic reviews, randomized clinical trials, cohort and case-control studies and validation studies were included. Quality was appraised using validated scales. RESULTS: There were only 3 US published studies in the literature that analysed US utility on assessment of response to treatment in patients with gout. All of them were prospective case studies with a small number of patients and they were reviewed in detailed. A total of 36 patients with gout were examined with US. All of them had a baseline serum urate >6mg/dL. US features of gout (double contour sign, hyperechoic spots in synovial fluid, hyperechoic cloudy areas, tophus diameter and volume) achieved significant reduction in patients who reached the objective of uricemia ≤6mg/dL in all the studies; however, patients in whom levels did not drop below 6mg/dL had no change of US features of gout. Other parameters evaluated in one study included ESR, CRP, number of tender joints (TRN), number of swollen joints, and pain score (SP). All of them decreased with uricemia reduction, but only TRN and SP were statistically significant. No data was found on the value of MRI on treatment response assessment in patients with gout. CONCLUSIONS: The improvement in ultrasound features shows concurrent validity with uric acid reduction. According to the published evidence, US can be a useful tool for monitoring treatment of gouty patients, although more research is needed. The value of MRI on treatment response assessment in patients with gout remains to be determined.
Subject(s)
Gout/diagnosis , Gout/drug therapy , Magnetic Resonance Imaging , Patient Outcome Assessment , Gout/diagnostic imaging , Humans , UltrasonographyABSTRACT
INTRODUCCIÓN. El cáncer de ovario ocupa el tercer lugar entre los cánceres ginecológicos y a él se debe el 5 por ciento de todas las muertes por cáncer. El objetivo del presente estudio fue conocer la incidencia hospitalaria, la respuesta al tratamiento y la supervivencia global del cáncer de ovario en nuestra institución, durante un quinquenio. MÉTODOS. Se realizó un estudio retrospectivo, descriptivo, lineal con 192 mujeres con tumores de ovario. Se excluyeron aquellas con tumores benignos o tumores no extirpables, y las que no recibieron tratamiento oncoespecífico o lo recibieron y fueron seguidas en otros hospitales. RESULTADOS. Los grupos etarios más afectados correspondieron al quinto y sexto decenios de la vida (40,4 ) y la media de edad fue de 48 años. La etapa clínica más frecuente fue la III (261 por ciento ) de las mujeres, y el 44,2 por ciento estaba en estadio IIIc. El tipo histológico más frecuente fue el adenocarcinoma papilar seroso (H" 70 por ciento ), entre los cánceres epiteliales (49; 94,23 por ciento ). La supervivencia global media de las pacientes que recibieron tratamiento quirúrgico fue de 31 meses. Al finalizar el estudio la tasa de supervivencia era menor del 40 por ciento . En las pacientes que no respondieron a la quimioterapia la supervivencia a los 36 meses fue nula. CONCLUSIONES. El comportamiento del cáncer ovárico en el Instituto Nacional de Oncología y Radiobiología de Cuba no difiere mucho de lo reportado en la literatura médica mundial(AU)
INTRODUCTION. Ovarian cancer occupies the third place among the gynecological cancers, and it causes 5 percent of all the deaths from cancer. The objective of this study is to know the hospital incidence, the response to the treatment and the global survival of ovarian cancer in our institution during a five-year term. METHODS. A descriptive, retrospective and lineal study was carried out among 192 females with ovarian tumors. Those with benign or non resectable tumors were excluded, as well as the patients that did not receive oncospecific treatment or that received it, but were followed-up in another hospital. RESULTS. The most affected age groups were in the fifth and sixth decades of life (40.4 percent). Mean age was 48 years old. The most common clinical stage was the stage III (261 percent of the females). 44.2 percent were at stage IIIc. The most frequent histological type was the serous papillary adenocarcinoma (H" 70 percent) among the epithelial cancers (49; 94.23 percent). The global mean survival of the patients that received surgical treatment was 31 months. At the end of the study, the survival rate was under 40 percent. Survival after the 36 months was null among the patients that did not respond to chemotherapy. CONCLUSIONS. The behavior of ovarian cancer at the National Institute of Oncology and Radiobiology does not differ to much from what is reported by the world medical literature(AU)
Subject(s)
Humans , Female , Middle Aged , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/therapy , Survival , Epidemiology, Descriptive , Retrospective Studies , SurvivorshipABSTRACT
El cáncer de ovario ocupa el tercer lugar entre los cánceres ginecológicos y a él se debe el 5 por ciento de todas las muertes por cáncer. El objetivo del presente estudio fue conocer la incidencia hospitalaria, la respuesta al tratamiento y la supervivencia global del cáncer de ovario en nuestra institución, durante un quinquenio. Se realizó un estudio retrospectivo, descriptivo, lineal con 192 mujeres con tumores de ovario. Se excluyeron aquellas con tumores benignos o tumores no extirpables, y las que no recibieron tratamiento oncoespecífico o lo recibieron y fueron seguidas en otros hospitales. Los grupos etarios más afectados correspondieron al quinto y sexto decenios de la vida (40,4 por ciento) y la media de edad fue de 48 años. La etapa clínica más frecuente fue la III (261 por ciento) de las mujeres, y el 44,2 por ciento estaba en estadio IIIc. El tipo histológico más frecuente fue el adenocarcinoma papilar seroso (H" 70 por ciento), entre los cánceres epiteliales (49; 94,23 por ciento). La supervivencia global media de las pacientes que recibieron tratamiento quirúrgico fue de 31 meses. Al finalizar el estudio la tasa de supervivencia era menor del 40 por ciento. En las pacientes que no respondieron a la quimioterapia la supervivencia a los 36 meses fue nula. El comportamiento del cáncer ovárico en el Instituto Nacional de Oncología y Radiobiología de Cuba no difiere mucho de lo reportado en la literatura médica mundial(AU)
Ovarian cancer occupies the third place among the gynecological cancers, and it causes 5 percent of all the deaths from cancer. The objective of this study is to know the hospital incidence, the response to the treatment and the global survival of ovarian cancer in our institution during a five-year term. A descriptive, retrospective and lineal study was carried out among 192 females with ovarian tumors. Those with benign or non resectable tumors were excluded, as well as the patients that did not receive oncospecific treatment or that received it, but were followed-up in another hospital. The most affected age groups were in the fifth and sixth decades of life (40,4 percent). Mean age was 48 years old. The most common clinical stage was the stage III (261 percent of the females). 44,2 percent were at stage IIIc. The most frequent histological type was the serous papillary adenocarcinoma (H" 70 percent) among the epithelial cancers (49; 94,23 percent). The global mean survival of the patients that received surgical treatment was 31 months. At the end of the study, the survival rate was under 40 percent. Survival after the 36 months was null among the patients that did not respond to chemotherapy. The behavior of ovarian cancer at the National Institute of Oncology and Radiobiology does not differ to much from what is reported by the world medical literature(AU)
